Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials

From the report

Nature Medicine, Published online: 03 November 2026; doi:10.1038/s41591-026-04743-6As presented at the Society for Immunotherapy of Cancer 2026 Annual Meeting, in a non-prespecified pooled analysis of two trials, amsokigene autoleucel, an autologous tumor-infiltrating lymphocyte therapy engineered to eliminate the need for IL-2, was successfully manufactured and well tolerated and showed a preliminary clinical efficacy signal in…